-- The partnership will provide commercial supply for a potential micro-dystrophin gene therapy product launch
and other neuromuscular programs in the pipeline --
-- Hybrid model enables Sarepta to maintain control over process development, while leveraging Brammer Bio’s
world-class manufacturing capabilities --
CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage
biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular
diseases, announced today that it has entered into a long-term strategic manufacturing partnership with Brammer Bio, which will
provide Sarepta access to clinical and commercial manufacturing capacity for its micro-dystrophin Duchenne muscular dystrophy (DMD)
gene therapy program and a manufacturing platform for future gene therapy programs, such as Limb girdle muscular dystrophy
(LGMD).
Sarepta has adopted a hybrid internal and external development and manufacturing model. Under this model,
Sarepta will continue to build internal expertise in all aspects of AAV-based manufacturing while externally Brammer Bio will
provide scalable best-in-class manufacturing capabilities. The collaboration model will integrate process development, clinical
production and testing, and commercial manufacturing with the goal of bringing micro-dystrophin gene therapies to the patient
community urgently and in sufficient supply.
Brammer Bio will partner with Sarepta to design and build dedicated commercial manufacturing capacity within
their facility with cutting-edge capabilities. Once complete, the facility is expected to provide robust manufacturing capacity to
support the unusually high demands typical for systemic administration of the micro-dystrophin therapy for DMD.
“As we have stated in the past, Sarepta is committed to becoming one of the most meaningful genetic medicine
companies in the world over the coming few years. The Brammer Bio partnership and dedicated gene therapy capacity, once complete,
will represent more annual gene therapy supply than any currently existing facility,” stated Doug Ingram, Sarepta’s president and
chief executive officer.
Mr. Ingram added, “At Sarepta, we pride ourselves in partnering with the best and brightest to advance our
mission. With that in mind, we are proud to have selected Brammer Bio as our partner because they are among the world’s most
advanced cGMP gene therapy manufacturers, with expertise that spans all aspects of AAV-based gene therapy development,
manufacturing and release. Our hybrid approach enables us to leverage both our internal expertise and capabilities and Brammer
Bio’s capacity and expertise, allowing for minimal changes to the process to accelerate therapies for patients with DMD and
LGMD.”
“Brammer is delighted to partner with Sarepta Therapeutics to use our team’s deep development, clinical and
commercial expertise to support the rapid development of Sarepta’s gene therapy products to serve patients in the United States and
globally,” said Mark Bamforth, Brammer Bio’s president and chief executive officer.
Brammer Bio’s team of 400+ operates in Massachusetts and Florida. The 74,000 square-foot early clinical campus
consists of three buildings in Alachua, Fla., comprised of a process development and analytical development facility, adjacent to
its cGMP Phase 1/2 clinical manufacturing operation with a third warehouse and office building. Brammer Bio’s cGMP facility has
been supporting gene therapy clinical development for 12 years at this location.
Brammer Bio has 165,000 square-feet of facilities in Massachusetts for Phase 3 and commercial cGMP viral vector
manufacturing. The facility located in Cambridge was built out late in 2017 and the facility in Lexington will be operational in
2019; both are supported by the warehouse and distribution center in Somerville.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of
precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the
development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please
visit www.sarepta.com.
About Brammer Bio
Brammer Bio provides clinical and commercial supply of viral vectors for in vivo gene and ex
vivo modified-cell based therapies, process and analytical development, and regulatory support, enabling large pharma and
biotech clients to accelerate the delivery of novel medicines to improve patient health. Brammer is owned by Ampersand Capital
Partners, the only institutional investor in the company, and its founders. For more information, please visit www.brammerbio.com.
Forward-Looking Statements
This press release contains "forward-looking statements." Any statements contained in this press release
that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates,"
"plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking
statements. These forward-looking statements include statements regarding the expectation that the partnership with
Brammer Bio will provide Sarepta access to clinical and commercial manufacturing capacity for its micro-dystrophin
DMD gene therapy program and a manufacturing platform for future gene therapy programs, such as LGMD;
Sarepta’s plan to continue to build internal expertise in all aspects of AAV-based manufacturing while Brammer Bio will
provide scalable best-in-class manufacturing capabilities; the collaboration model integrating
process development, clinical production and testing, and commercial manufacturing with the goal of bringing micro-dystrophin
gene therapies to the patient community urgently and in sufficient supply; the expectation that Brammer Bio’s
facility will provide robust manufacturing capacity to support the unusually high demands typical for
systemic administration of the micro-dystrophin therapy for DMD; Sarepta’s commitment to becoming one of the most
meaningful genetic medicine companies in the world over the coming few years; the expectation that the Brammer
Bio partnership and dedicated gene therapy capacity, once complete, will represent more annual gene therapy supply than
any currently existing facility; and the hybrid approach allowing Sarepta for minimal
changes to the process to accelerate therapies for patients with DMD and LGMD.
These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s
control. Known risk factors include, among others: the expected benefits and opportunities related to the agreement with
Brammer Bio may not be realized or may take longer to realize than expected; Sarepta’s
dependence on Brammer Bio to produce its product candidates, including any inability on
Sarepta’s part to accurately anticipate product demand and timely secure manufacturing capacity to meet product
demand, may impair the availability of product to successfully support various programs, including research and development and the
potential commercialization of Sarepta’s gene therapy product candidates; if Brammer Bio were to cease
providing quality manufacturing and related services to Sarepta, and Sarepta is not able to engage appropriate replacements in a
timely manner, Sarepta’s ability to manufacture its gene therapy product candidates in sufficient quality and quantity would
adversely affect Sarepta’s various product research, development and commercialization efforts; if Brammer Bio
fails to adhere to applicable cGMP and other applicable government regulations, or experiences manufacturing
problems, Sarepta will suffer significant consequences, which could significantly delay or negatively impact the
success of Sarepta’s development efforts for its product candidates; Sarepta may not be able to successfully scale up manufacturing
of its product candidates in sufficient quality and quantity or within sufficient timelines, or be able to secure ownership of
intellectual property rights developed in this process, which could negatively impact the development of its product candidates and
next generation chemistries like gene therapy; Sarepta’s gene therapy programs may not result in any viable
treatments suitable for clinical research or commercialization due to a variety of reasons, including the results of future
research may not be consistent with past positive results or may fail to meet regulatory approval requirements for the safety and
efficacy of product candidates or may never become commercialized products due to other various reasons including possible
limitations of Company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a
timely manner, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with
respect to patents that cover our product candidates; and even if Sarepta’s gene therapy programs result in new commercialized
products, Sarepta may not achieve any significant revenues from the sale of such products; and those risks identified under the
heading “Risk Factors” in Sarepta’s most recent Annual Report on Form 10-K for the year ended December 31, 2017 and most
recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings
made by the Company which you are encouraged to review.
Any of the foregoing risks could materially and adversely affect the Company’s business, results of
operations and the trading price of Sarepta’s common stock. For a detailed description of risks and uncertainties Sarepta
faces, you are encouraged to review Sarepta's 2017 Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q filed
with the SEC as well as other SEC filings made by Sarepta. We caution investors not to place considerable reliance on the
forward-looking statements contained in this press re-lease. Sarepta does not undertake any obligation to publicly update its
forward-looking statements based on events or circumstances after the date hereof.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our
website at www.sarepta.com. We encourage investors and potential investors to consult our
website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
iestepan@sarepta.com
or
W2O Group
Brian Reid, 212-257-6725
breid@w2ogroup.com
For Brammer Bio
Erin Morton, APR, CPRC
Manager, Corporate Communications
Office: 386-418-8199 x2083
Mobile: 352-519-8351
erin.morton@brammerbio.com
